Market Overview

Movers From Yesterday

  • ADMA, AMRS, AXSM, BIIB, BLCM, BPMX

    60 Biggest Movers From Yesterday

    Friday, March 22, 2019 - 5:36am

    Gainers SPI Energy Co., Ltd. (NASDAQ: SPI) shares jumped 60.92 percent to close at $4.20 on Thursday after the company announced an amendment to its 2017 merger agreement with Thermi Sun which will delay the acquisition no later than May 20th. Phunware Inc. (NASDAQ: PHUN) gained 58.16 percent to...

    Read More...
  • AIR, AMRS, AVCO, BCOM, BIOS, BLCM

    52 Biggest Movers From Yesterday

    Thursday, March 21, 2019 - 4:59am

    Gainers Motif Bio plc (NASDAQ: MTFB) shares climbed 55.28 percent to close at $2.50 on Wednesday after the FDA granted the company's request for a Type A meeting to discuss the complete response letter regarding iclaprim. Nevro Corp. (NASDAQ: NVRO) gained 35.67 percent to close at $60.74 after...

    Read More...
  • ALT, AMD, AQB, ARAV, ARCE, ASRT

    70 Biggest Movers From Yesterday

    Wednesday, March 20, 2019 - 5:36am

    Gainers Vaxart, Inc. (NASDAQ: VXRT) shares surged 42.11 percent to close at $2.34 on Tuesday after the company initiated a Phase 1b clinical trial for its bivalent norovirus vaccine. Sorrento Therapeutics, Inc. (NASDAQ: SRNE) shares gained 39.64 percent to close at $3.84. IMAC Holdings, Inc. (...

    Read More...
  • ACRS, ADIL, ADMP, AKTX, AMID, APPS

    60 Biggest Movers From Yesterday

    Tuesday, March 19, 2019 - 5:24am

    Gainers Dare Bioscience Inc (NASDAQ: DARE) shares climbed 131.11 percent to close at $2.10 on Monday after the company published positive clinical findings for Tamoxifen for the treatment of vulvar and vaginal atrophy in a medical journal. Dermira, Inc. (NASDAQ: DERM) shares gained 82.16 percent...

    Read More...
  • AIHS, ALOT, ANY, AQB, AQST, ATOS

    71 Biggest Movers From Yesterday

    Friday, March 15, 2019 - 5:24am

    Gainers Atossa Genetics Inc (NASDAQ: ATOS) shares climbed 368.21 percent to close at $7.07 on Thursday after the company received FDA approval of oral Endoxifen for 'expanded access' as a post-mastectomy treatment for a US breast cancer patient. WageWorks, Inc. (NYSE: WAGE) shares climbed...

    Read More...
  • ACB, AERI, AKTX, AMPH, AMRX, ANY

    68 Biggest Movers From Yesterday

    Thursday, March 14, 2019 - 5:22am

    Gainers Akari Therapeutics PLC (NASDAQ: AKTX) shares jumped 224.18 percent to close at $5.90 on Wednesday after the company had a successful Type B, pre-IND meeting with the FDA regarding Akari's proposed pivotal clinical trial program for hematopoietic stem cell transplant-related thrombotic...

    Read More...
  • ADT, AGFS, AKBA, ALDX, ALTM, ANY

    56 Biggest Movers From Yesterday

    Wednesday, March 13, 2019 - 6:04am

    Gainers ENDRA Life Sciences Inc. (NASDAQ: NDRA) shares climbed 38.95 percent to close at $2.64 on Tuesday after reporting full-year 2018 earnings of $(2.17), up from $(1.95) in 2017. HyreCar Inc. (NASDAQ: HYRE) gained 28.39 percent to close at $7.10. SAExploration Holdings, Inc. (NASDAQ: SAEX)...

    Read More...
  • AFH, ALQA, APOP, AQB, ARA, AUTO

    50 Biggest Movers From Yesterday

    Tuesday, March 12, 2019 - 5:04am

    Gainers Globus Maritime Limited (NASDAQ: GLBS) shares gained 92.34 percent to close at $8.54 on Monday after surging 33.94 percent on Friday. Bio-Path Holdings, Inc. (NASDAQ: BPTH) shares jumped 54.48 percent to close at $32.44. Organogenesis Holdings Inc. (NASDAQ: ORGO) rose 37.7 percent to...

    Read More...
  • ACMR, ALT, APTX, APVO, AQXP, ARDX

    64 Biggest Movers From Yesterday

    Friday, March 8, 2019 - 6:22am

    Gainers Bio-Path Holdings, Inc. (NASDAQ: BPTH) shares surged 223.29 percent to close at $38.86 on continued strength after the company on Wednesday announced BP1001 for the treatment of acute myeloid leukemia demonstrated 'meaningful clinical improvement' with an 'excellent'...

    Read More...
  • ABEO, AGS, ALNY, ALT, ANF, AON

    58 Biggest Movers From Yesterday

    Thursday, March 7, 2019 - 5:55am

    Gainers Bio-Path Holdings Inc (NASDAQ: BPTH) shares surged 160.46 percent to close at $12.02 on Wednesday after the company's Phase 2 trial of BP1001 for the treatment of acute myeloid leukemia demonstrated 'meaningful clinical improvement' with an 'excellent' patient safety...

    Read More...